Viral Hepatitis C - Idenix Provides Update on Clinical Development of Valopicitabine (NM283) for the Treatment of Hepatitis C

Idenix Provides Update on Clinical Development of Valopicitabine (NM283) for the Treatment of Hepatitis C
FinanzNachrichten - Mar 23 2:09 PM
CAMBRIDGE, Mass., March 23 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, ( Nachrichten ) Inc. , a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases, announced today an update on its clinical development program for valopicitabine (NM283) for the treatment of hepatitis C. Idenix has Save to My Web

Govt accused of breaking promise to pursue drug firms
Irish Examiner - Mar 23 2:51 AM
The Irish Haemophilia Society (IHS) is reportedly accusing the Government of failing to pursue pharmaceutical firms that sold contaminated products to the Irish Blood Transfusion Service.Save to My Web

Hepatitis C Victims 'Could Hit 1m'
RedNova - Mar 23 5:33 AM
THERE could be five times the number of people infected with hepatitis C than current estimates suggest, an expert warned yesterday.Save to My Web

BioScrip to Report Fourth Quarter and Year End 2005 Earnings on March 29
[Press Release] Business Wire via Yahoo! Finance - Mar 27 9:59 AM
ELMSFORD, N.Y.----March 27, 2006--BioScrip, Inc. announced today that it will report its fourth quarter and year end earnings for the period ended December 31, 2005, before market open on March 29, 2006.Save to My Web

Human Genome Sciences Shares Fall After Early Hepatitis C Treatment Data Released
Money Sense - Mar 14 8:39 AM
Shares of Human Genome Sciences Inc. dropped Tuesday as investors showed displeasure with preliminary mid-stage results showing the biotech company's interferon product produced comparable results to the standard of care for new hepatitis C patients.Save to My Web